Bone and muscle: Interactions beyond mechanical

Bone

Volumn 80, Issue , 2015, Pages 109-114

  Brotto, Marco ^a,c   Bonewald, Lynda ^b  

^a Muscle Biology Research Group MUBIG   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF DENTISTRY   (United States)

Author keywords

Bone; Bone muscle crosstalk; Gene pleiotropy; Muscle; Secreted factors

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; MYOSTATIN;

BIOCHEMISTRY; BONE; BONE MUSCLE CROSSTALK; DISEASE ASSOCIATION; FRACTURE HEALING; GENE; GENETIC ASSOCIATION; HUMAN; MEF2C GENE; METTL21C GENE; MOLECULAR INTERACTION; MUSCLE; MUSCLE FUNCTION; MUSCLE HYPERTROPHY; MUSCLE WEAKNESS; MYOBLAST; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS; PLEIOTROPY; REVIEW; SARCOPENIA; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SKELETAL MUSCLE; ANIMAL; BIOMECHANICS; METABOLISM; PHYSIOLOGY;

ANIMALS; BIOMECHANICAL PHENOMENA; BONE AND BONES; HUMANS; MUSCLE, SKELETAL;

EID: 84943605262     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2015.02.010     Document Type: Review

References (81)

1. Bonewald L.F., Kiel D.P., Clemens T.L., Esser K., Orwoll E.S., O'Keefe R.J., et al. Forum on bone and skeletal muscle interactions: summary of the proceedings of an ASBMR workshop. J Bone Miner Res 2013, 28(9):1857-1865.
2. Benefield L.E., Holtzclaw B.J. Aging in place: merging desire with reality. Nurs Clin North Am 2014, 49(2):123-131.
3. Economic and Social Affairs, World Population Prospects 2004, The 2002 Revision, Vol III, Analytical Report, United Nations Publication, New York, http://www.un.org/esa/population/publications/wpp2002/WPP2002_VOL_3.pdf.
4. Pourquié O. Vertebrate somitogenesis. Annu Rev Cell Dev Biol 2001, 17(1):311-350.
5. Rauch F., Schoenau E. The developing bone: slave or master of its cells and molecules?. Pediatr Res 2001, 50(3):309-314.
6. Land C., Schoenau E. Fetal and postnatal bone development: reviewing the role of mechanical stimuli and nutrition. Best Pract Res Clin Endocrinol Metab 2008, 22(1):107-118.
7. Kurek J.B., Bower J.J., Romanella M., Koentgen F., Murphy M., Austin L. The role of leukemia inhibitory factor in skeletal muscle regeneration. Muscle Nerve 1997, 20(7):815-822.
8. Allen D.L., Cleary A.S., Speaker K.J., Lindsay S.F., Uyenishi J., Reed J.M., et al. Myostatin, activin receptor IIb, and follistatin-like-3 gene expression are altered in adipose tissue and skeletal muscle of obese mice. Am J Physiol Endocrinol Metab 2008, 294(5):E918-E927.
9. Pedersen B.K. Muscle as a secretory organ. Compr Physiol 2013, 3(3):1337-1362.
10. Pedersen B.K., Akerstrom T.C., Nielsen A.R., Fischer C.P. Role of myokines in exercise and metabolism. J Appl Physiol 2007, 103(3):1093-1098.
11. Pedersen L., Olsen C.H., Pedersen B.K., Hojman P. Muscle-derived expression of the chemokine CXCL1 attenuates diet-induced obesity and improves fatty acid oxidation in the muscle. Am J Physiol Endocrinol Metab 2012, 302(7):E831-E840.
12. Seale P., Bjork B., Yang W., Kajimura S., Chin S., Kuang S., et al. PRDM16 controls a brown fat/skeletal muscle switch. Nature 2008, 454(7207):961-967.
13. Quinn L.S., Anderson B.G., Strait-Bodey L., Stroud A.M., Argiles J.M. Oversecretion of interleukin-15 from skeletal muscle reduces adiposity. Am J Physiol Endocrinol Metab 2009, 296(1):E191-E202.
14. Jahn K., Lara-Castillo N., Brotto L., Mo C.L., Johnson M.L., Brotto M., et al. Skeletal muscle secreted factors prevent glucocorticoid-induced osteocyte apoptosis through activation of beta-catenin. Eur Cell Mater 2012, 24:197-209. [discussion -10].
15. Dallas S.L., Prideaux M., Bonewald L.F. The osteocyte: an endocrine cell . . . and more. Endocr Rev 2013, 34(5):658-690.
16. Linkhart T.A., Mohan S., Baylink D.J. Growth factors for bone growth and repair: IGF, TGF beta and BMP. Bone 1996, 19(1 Suppl):1S-12S.
17. Lee N.K., Sowa H., Hinoi E., Ferron M., Ahn J.D., Confavreux C., et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007, 130(3):456-469.
18. Ferron M., Wei J., Yoshizawa T., Del Fattore A., DePinho R.A., Teti A., et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 2010, 142(2):296-308.
19. Karsenty G., Ferron M. The contribution of bone to whole-organism physiology. Nature 2012, 481(7381):314-320.
20. Klein-Nulend J., Bonewald L.F. The osteocyte. Principles of bone biology 2008, 1. Academic Press. J.P. Bilezikian, L.G. Raisz (Eds.).
21. Kramer I., Halleux C., Keller H., Pegurri M., Gooi J.H., Weber P.B., et al. Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol 2010, 30(12):3071-3085.
22. Bonewald L.F., Johnson M.L. Osteocytes, mechanosensing, and Wnt signaling. Bone 2008, 42:606-615.
23. Jahn K., Lara-Castillo N., Brotto L., Mo C.L., Johnson M.L., Brotto M., et al. Skeletal muscle secreted factors prevent glucocorticoid-induced osteocyte apoptosis through activation of beta-catenin. Eur Cell Mater 2012, 24:197-210.
24. Mo C., Romero-Suarez S., Bonewald L., Johnson M., Brotto M. Prostaglandin E2: from clinical applications to its potential role in bone-muscle crosstalk and myogenic differentiation. Recent Pat Biotechnol 2012, 6(3):223-229.
25. Mo C.L., Romero-Suarez S., Bonewald L.F., Johnson M.L., Brotto M. Evidence for biochemical and functional communication from the MLO-Y4 osteocyte-like cell to the C2C12 muscle cells. Cell cycle 2012, [In Submission].
26. Huang J., Mo C., Bonewald L., Brotto M. Wnt3a potentiates myogenesis in C2C12 myoblasts through changes of signaling pathways including Wnt and NFkB. ASBMR 2014 Annual Meeting 2014, [SU0190:s266].
27. Shimada T., Kakitani M., Yamazaki Y., Hasegawa H., Takeuchi Y., Fujita T., et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004, 113(4):561-568.
28. Feng J.Q., Ward L.M., Liu S., Lu Y., Xie Y., Yuan B., et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 2006, 38(11):1310-1315.
29. Liu S., Lu Y., Xie Y., Zhou J., Quarles L.D., Bonewald L., et al. Elevated levels of FGF23 in dentin matrix protein 1 (DMP1) null mice potentially explain phenotypic similarities to Hyp mice. J Bone Miner Res 2006, 21:S51.
30. Riminucci M., Collins M.T., Fedarko N.S., Cherman N., Corsi A., White K.E., et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 2003, 112(5):683-692.
31. Bonewald L.F. Osteocytes as dynamic, multifunctional cells. Ann N Y Acad Sci 2007, 1116:281-290.
32. Krajisnik T., Bjorklund P., Marsell R., Ljunggren O., Akerstrom G., Jonsson K.B., et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007, 195(1):125-131.
33. Ben-Dov I.Z., Galitzer H., Lavi-Moshayoff V., Goetz R., Kuro-o M., Mohammadi M., et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007, 117(12):4003-4008.
34. Mirza M.A., Larsson A., Lind L., Larsson T.E. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009, 205(2):385-390.
35. Faul C., Amaral A.P., Oskouei B., Hu M.C., Sloan A., Isakova T., et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011, 121(11):4393-4408.
36. Desjardins L., Liabeuf S., Renard C., Lenglet A., Lemke H.D., Choukroun G., et al. FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int 2011, 23(7):2017-2025.
37. Mirza M.A., Alsio J., Hammarstedt A., Erben R.G., Michaelsson K., Tivesten A., et al. Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler Thromb Vasc Biol 2011, 31(1):219-227.
38. Zacks S.I., Sheff M.F. Periosteal and metaplastic bone formation in mouse minced muscle regeneration. Lab Invest 1982, 46(4):405-412.
39. Westbroek I., van der Plas A., de Rooij K.E., Klein-Nulend J., Nijweide P.J. Expression of serotonin receptors in bone. J Biol Chem 2001, 276(31):28961-28968.
40. Utvag S.E., Iversen K.B., Grundnes O., Reikeras O. Poor muscle coverage delays fracture healing in rats. Acta Orthop Scand 2002, 73(4):471-474.
41. Yamashiro T., Fukunaga T., Kobashi N., Kamioka H., Nakanishi T., Takigawa M., et al. Mechanical stimulation induces CTGF expression in rat osteocytes. J Dent Res 2001, 80(2):461-465.
42. Harry L.E., Sandison A., Paleolog E.M., Hansen U., Pearse M.F., Nanchahal J. Comparison of the healing of open tibial fractures covered with either muscle or fasciocutaneous tissue in a murine model. J Orthop Res 2008, 26(9):1238-1244.
43. Chen D., Chen H., Feng J.Q., Windle J.J., Koop B.A., Harris M.A., et al. Osteoblastic cell lines derived from a transgenic mouse containing the osteocalcin promoter driving SV40 T-antigen. Mol Cell Differ 1995, 3:193-212.
44. Schindeler A., Liu R., Little D.G. The contribution of different cell lineages to bone repair: exploring a role for muscle stem cells. Differentiation 2009, 77(1):12-18.
45. Liu R., Schindeler A., Little D.G. The potential role of muscle in bone repair. J Musculoskelet Neuronal Interact 2010, 10(1):71-76.
46. Grobet L., Royo Martin L.J., Poncelet D., Pirottin D., Brouwers B., Riquet J., et al. A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nat Genet 1997, 17(1):71-74.
47. Kambadur R., Sharma M., Smith T.P.L., Bass J.J. Mutations in myostatin (GDF8) in Double-Muscled Belgian Blue and Piedmontese Cattle. Genome Res 1997, 7(9):910-915.
48. McPherron A.C., Lee S.-J. Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci 1997, 94(23):12457-12461.
49. Clop A., Marcq F., Takeda H., Pirottin D., Tordoir X., Bibe B., et al. A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nat Genet 2006, 38(7):813-818.
50. Mosher D.S., Quignon P., Bustamante C.D., Sutter N.B., Mellersh C.S., Parker H.G., et al. A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet 2007, 3(5):e79.
51. Zhang G.X., Zhao X.H., Wang J.Y., Ding F.X., Zhang L. Effect of an exon 1 mutation in the myostatin gene on the growth traits of the Bian chicken. Anim Genet 2012, 43(4):458-459.
52. Williams M. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 2004, 351(10):1030-1031.
53. Pedersen B.K., Febbraio M.A. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol 2012, 8(8):457-465.
54. Elkasrawy M., Fulzele S., Bowser M., Wenger K., Hamrick M. Myostatin (GDF-8) inhibits chondrogenesis and chondrocyte proliferation in vitro by suppressing Sox-9 expression. Growth Factors 2011, 29(6):253-262.
55. Elkasrawy M.N., Hamrick M.W. Myostatin (GDF-8) as a key factor linking muscle mass and bone structure. J Musculoskelet Neuronal Interact 2010, 10(1):56-63.
56. Buehring B., Binkley N. Myostatin-the holy grail for muscle, bone, and fat?. Curr Osteoporos Rep 2013, 11(4):407-414.
57. Bialek P., Parkington J., Li X., Gavin D., Wallace C., Zhang J., et al. A myostatin and activin decoy receptor enhances bone formation in mice. Bone 2014, 60:162-171.
58. Karasik D., Zhou Y., Cupples L.A., Hannan M.T., Kiel D.P., Demissie S. Bivariate genome-wide linkage analysis of femoral bone traits and leg lean mass: Framingham study. J Bone Miner Res 2009, 24(4):710-718.
59. Karasik D., Kiel D.P. Evidence for pleiotropic factors in genetics of the musculoskeletal system. Bone 2010, 46(5):1226-1237.
60. Gupta M., Cheung C.-L., Hsu Y.-H., Demissie S., Cupples L.A., Kiel D.P., et al. Identification of homogeneous genetic architecture of multiple genetically correlated traits by block clustering of genome-wide associations. J Bone Miner Res 2011, 26(6):1261-1271.
61. Sun L., Tan L.-J., Lei S.-F., Chen X.-D., Li X., Pan R., et al. Bivariate genome-wide association analyses of femoral neck bone geometry and appendicular lean mass. PLoS ONE 2011, 6(11):e27325.
62. Karasik D., Cohen-Zinder M. Osteoporosis genetics: year 2011 in review. Bonekey Rep 2012, 1. [Article Number: 114:1-5].
63. Guo Y.-F., Zhang L.-S., Liu Y.-J., Hu H.-G., Li J., Tian Q., et al. Suggestion of GLYAT gene underlying variation of bone size and body lean mass as revealed by a bivariate genome-wide association study. Hum Genet 2013, 132(2):189-199.
64. Edmondson D.G., Lyons G.E., Martin J.F., Olson E.N. Mef2 gene expression marks the cardiac and skeletal muscle lineages during mouse embryogenesis. Development 1994, 120(5):1251-1263.
65. Kramer I., Baertschi S., Halleux C., Keller H., Kneissel M. Mef2c deletion in osteocytes results in increased bone mass. J Bone Miner Res 2012, 27(2):360-373.
66. Huang J., Hsu Y.H., Mo C., Abreu E., Kiel D.P., Bonewald L.F., et al. METTL21C is a potential pleiotropic gene for osteoporosis and sarcopenia acting through the modulation of the NF-kappaB signaling pathway. J Bone Miner Res 2014, 29(7):1531-1540.
67. Kernstock S., Davydova E., Jakobsson M., Moen A., Pettersen S., Maelandsmo G.M., et al. Lysine methylation of VCP by a member of a novel human protein methyltransferase family. Nat Commun 2012, 3:1038.
68. Cloutier P., Lavallee-Adam M., Faubert D., Blanchette M., Coulombe B. A newly uncovered group of distantly related lysine methyltransferases preferentially interact with molecular chaperones to regulate their activity. PLoS Genet 2013, 9(1):e1003210.
69. Rauch F., Glorieux F.H. Osteogenesis imperfecta. Lancet 2004, 363(9418):1377-1385.
70. Gentry B.A., Ferreira J.A., McCambridge A.J., Brown M., Phillips C.L. Skeletal muscle weakness in osteogenesis imperfecta mice. Matrix Biol 2010, 29(7):638-644.
71. Donohoe M., Cintas H. Ankle strength and functional limitations in children and adolescents with type I osteogenesis imperfecta. Pediatr Phys Ther 2010, 22(3):295.
72. Caudill A., Flanagan A., Hassani S., Graf A., Bajorunaite R., Harris G., et al. Ankle strength and functional limitations in children and adolescents with type I osteogenesis imperfecta. Pediatr Phys Ther 2010, 22(3):288-295.
73. Boot A.M., de Coo R.F., Pals G., de Muinck Keizer-Schrama S.M. Muscle weakness as presenting symptom of osteogenesis imperfecta. Eur J Pediatr 2006, 165(6):392-394.
74. Mirza M.A., Larsson A., Melhus H., Lind L., Larsson T.E. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 2009, 207(2):546-551.
75. Shen H., Grimston S., Civitelli R., Thomopoulos S. Deletion of connexin 43 in osteoblasts/osteocytes leads to imparied muscle formation in mice. J Bone Min Res 2015, [epub].
76. Levinger I., Scott D., Nicholson G.C., Stuart A.L., Duque G., McCorquodale T., et al. Undercarboxylated osteocalcin, muscle strength and indices of bone health in older women. Bone 2014, 64:8-12.
77. Levinger I., Zebaze R., Jerums G., Hare D.L., Selig S., Seeman E. The effect of acute exercise on undercarboxylated osteocalcin in obese men. Osteoporos Int 2011, 22(5):1621-1626.
78. Fernandez-Real J.M., Izquierdo M., Ortega F., Gorostiaga E., Gomez-Ambrosi J., Moreno-Navarrete J.M., et al. The relationship of serum osteocalcin concentration to insulin secretion, sensitivity, and disposal with hypocaloric diet and resistance training. J Clin Endocrinol Metab 2009, 94(1):237-245.
79. Bell L.S., Kayser M., Jones C. The mineralized osteocyte: a living fossil. Am J Phys Anthropol 2008, 137(4):449-456.
80. Qiu S., Rao D.S., Palnitkar S., Parfitt A.M. Reduced iliac cancellous osteocyte density in patients with osteoporotic vertebral fracture. J Bone Miner Res 2003, 18(9):1657-1663.
81. Busse B., Djonic D., Milovanovic P., Hahn M., Puschel K., Ritchie R.O., et al. Decrease in the osteocyte lacunar density accompanied by hypermineralized lacunar occlusion reveals failure and delay of remodeling in aged human bone. Aging Cell 2010, 9(6):1065-1075.